Company Overview and News
The Canada-based drug company is changing its name on Jul. 1 to Bausch Health Corp. That, along with the new ticker symbol (BHC), is supposed to put the company’s past behind it once and for all, leading to growth and profit for investors.
The following slide deck was published by Perrigo Company in conjunction with their 2018 Q1 earnings call.
Perrigo Company plc (PRGO - Free Report) reported first-quarter 2018 adjusted earnings of 57 cents per share, which missed the Zacks Consensus Estimate of $1.14 by 50%. The bottom line, however, increased 14% from the year-ago figure of 50 cents.
BRK.A LGNZZ LGND PRGO LGNYZ LGNXZ PTGX ILMN LGNDZ
Good morning. My name is Justin, and I will be your conference operator today. At this time I would like to welcome everyone to the Perrigo First Quarter 2018 Financial Results. Thank you. Mr. Brad Joseph, you may begin your conference.
DB MS.PRI MS.PRK PRGO MS.PRE MS.PRF MS.PRG MS MS.PRA
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION<
We expectPerrigo Company plc (PRGO - Free Report) to beat estimates when it reports first-quarter 2018 results before the opening bell on May 8.
WFC WFCNP UNM WFC.WS AZN EBS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR AZN WFC.PRQ WFC.PRP WFC.PRO WFC.PRN PRGO ADVM WFC.PRY WFC.PRX WFC.PRW WFC.PRV
A review of Jeffrey Smith’s investing strategy and take a look inside Starboard Value’s stock portfolio. Largest holdings include Perrigo Company PLC (NYSE: PRGO), Altaba Inc (Nasdaq: AABA), and Marvell Technology Group Ltd. (Nasdaq: MRVL).
MRVL MLNX PRGO DRI CARS BCO
If the St. Patrick’s Day observances have investors pondering opportunities in the Emerald Isle, there are a few things to know. First, Ireland has been known for some time for its low corporate tax rate, which even prompted some U.S. companies to move their headquarters there. That was often accomplished by means of a so-called tax inversion, in which a merger or acquisition allows the company to claim the headquarters of the Irish (or other foreign) partner as its own.
IR.WI ADNT STX ETN MDT SHPG IR PRGO ACN JCI HZNP INGERRAND 500210
21h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to PRGO / Perrigo Company plc on message board site Silicon Investor.
|PRGO: Perrigo Company|
as of ET